Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, "Toripalimab's approval in Singapore represents our ...
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, ...
The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
Zacks Investment Research on MSN13h
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...
Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback